120 EYE AREA CARE A 0 days 28 days
28 days 0 days
B Placebo 0
-2 -4 -6 -8
-10
vs initial time: ***p<0.05 vs placebo: *p<0.05
-8.4% -42.9%
****
Figure 7: A) Representative images of the infraorbital area obtained at baseline and after 28 days of treatment with the AI-designed peptide during a clinical study. The superimposed contours highlight the reduction in eye bag area after treatment. B) Change in eye bag volume measured with a 3D image system
Mechanistic studies demonstrated that the AI- designed peptide acts across seven interconnected soft tissues: vascular system, lymphatic system, epidermis, dermis, adipose tissue, muscle and ligament-support structures. The activity profile includes reduced vascular
and lymphatic permeability, reinforcement of the epidermal barrier, reduction of melanin accumulation, enhancement of dermal matrix markers, decreased adipocyte lipid content, increased muscle energization and regeneration markers, and restoration of ligament-associated extracellular matrix components. By addressing an upstream biological mechanism linked to permeability, inflammation and tissue homeostasis, this approach supports a new paradigm in eye contour care: targeting the periocular microenvironment rather than individual visible signs of ageing. Together, these findings support a shift from conventional symptom-driven approaches toward a biology-driven strategy for eye contour rejuvenation.
A 0 days 7 days 0 B 0 days 7 days
-2 -4 -6 -8
-10 -12 -14
vs initial time: ****p<0.0001 -8.9% **** - **** 12.3% ■ Placebo ■ 2% Eyeseryl All-In peptide solution
Figure 8: Clinical improvement in crow’s feet wrinkles and upper eyelid appearance after seven days of treatment. (A) Representative eye contour images. (B) Change in crow’s feet wrinkle volume measured by PRIMOS 3D fringe projection analysis. (C) Increased eye opening and improved upper eyelid appearance
PERSONAL CARE MAGAZINE October 2026
www.personalcaremagazine.com
References 1. Sakata A, Abe K, Mizukoshi K, Gomi T, Okuda I. Relationship between the retinacula cutis and sagging facial skin. Skin Res Technol. 2018;24:93-98
2. Alghoul M, Codner MA. Retaining ligaments of the face: review of anatomy and clinical applications. Aesthetic Surg J. 2013;33(6):769- 782. doi:10.1177/1090820X13495405
3. Rabiet MJ, Plantier JL, Rival Y, Genoux Y, Lampugnani MG, Dejana E. Thrombin- induced increase in endothelial permeability is associated with changes in cell-to-cell junction organization. Arterioscler Thromb Vasc Biol. 1996;16(3):488-496
4. Bonnet I, Jobeili L, Cadau S, Berthelemy N, Pierrot A, Tedeschi C, et al. Collagen XVIII: A key interfacial component of the skin architecture. J Cosmet Sci. 2017;68:35-41
PCM
5. Schiavinato A, Marcous F, Zuk AV, Keene DR, Tufa SF, Mosquera LM, et al. New insights into the structural role of EMILINs within the human
C 7 days 28 days skin microenvironment. Sci Rep. 2024;14:30345.
6. Ye L, Yao Y, Guo H, Peng Y. Exogenous skeletal muscle satellite cells promote the repair of levator palpebrae superioris mechanical damage in rat. Connect Tissue Res. 2019;60(2):128-135
7. Yoshida T, Delafontaine P. Mechanisms of IGF-1-mediated regulation of skeletal muscle hypertrophy and atrophy. Cells. 2020;9(9):1970.
8. Mestre R, García N, Patiño T, Guix M, Fuentes J, Valerio-Santiago M, et al. 3D-bioengineered model of human skeletal muscle tissue with phenotypic features of aging for drug testing purposes. Biofabrication. 2021;13(4):045003.
9. Scicchitano BM, Rizzuto E, Musarò A. Counteracting muscle wasting in aging and neuromuscular diseases: the critical role of IGF- 1. Aging. 2009;1(5):451-457
10. Osakabe T, Hayashi M, Hasegawa K, Okuaki T, Ritty TM, Mecham RP, et al. Age- and gender- related changes in ligament components. Ann Clin Biochem. 2001;38(Pt 5):527-532
All-In peptide solution
2% Eyeseryl
Crow’s feet wrinkles volume Variation (%)
Volume Variation (%)
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97 |
Page 98 |
Page 99 |
Page 100 |
Page 101 |
Page 102 |
Page 103 |
Page 104 |
Page 105 |
Page 106 |
Page 107 |
Page 108 |
Page 109 |
Page 110 |
Page 111 |
Page 112 |
Page 113 |
Page 114 |
Page 115 |
Page 116 |
Page 117 |
Page 118 |
Page 119 |
Page 120 |
Page 121 |
Page 122 |
Page 123 |
Page 124 |
Page 125 |
Page 126 |
Page 127 |
Page 128 |
Page 129 |
Page 130 |
Page 131 |
Page 132
